Biotechnology Privately-held, US-based quiescent cancer drug and diagnostics developer Felicitex Therapeutics has entered into a strategic collaboration with Poland-based biotech firm Selvita, to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors. 7 November 2014